BIODESIX INC (BDSX) Stock Fundamental Analysis

NASDAQ:BDSX • US09075X2071

13.19 USD
+0.44 (+3.45%)
At close: Feb 20, 2026
13.19 USD
0 (0%)
After Hours: 2/20/2026, 8:18:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BDSX. BDSX was compared to 101 industry peers in the Health Care Providers & Services industry. BDSX has a bad profitability rating. Also its financial health evaluation is rather negative. BDSX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • BDSX had negative earnings in the past year.
  • BDSX had a negative operating cash flow in the past year.
  • In the past 5 years BDSX always reported negative net income.
  • BDSX had a negative operating cash flow in each of the past 5 years.
BDSX Yearly Net Income VS EBIT VS OCF VS FCFBDSX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -44.56%, BDSX is not doing good in the industry: 88.12% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -44.56%
ROE N/A
ROIC N/A
ROA(3y)-55.74%
ROA(5y)-49.96%
ROE(3y)-553.97%
ROE(5y)-391.42%
ROIC(3y)N/A
ROIC(5y)N/A
BDSX Yearly ROA, ROE, ROICBDSX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

  • The Gross Margin of BDSX (79.82%) is better than 94.06% of its industry peers.
  • BDSX's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for BDSX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.1%
GM growth 5Y0.76%
BDSX Yearly Profit, Operating, Gross MarginsBDSX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • BDSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BDSX has been increased compared to 1 year ago.
  • The number of shares outstanding for BDSX has been increased compared to 5 years ago.
  • Compared to 1 year ago, BDSX has a worse debt to assets ratio.
BDSX Yearly Shares OutstandingBDSX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
BDSX Yearly Total Debt VS Total AssetsBDSX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • BDSX has an Altman-Z score of -7.19. This is a bad value and indicates that BDSX is not financially healthy and even has some risk of bankruptcy.
  • BDSX has a Altman-Z score of -7.19. This is amonst the worse of the industry: BDSX underperforms 87.13% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.19
ROIC/WACCN/A
WACC11.12%
BDSX Yearly LT Debt VS Equity VS FCFBDSX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

  • BDSX has a Current Ratio of 1.84. This is a normal value and indicates that BDSX is financially healthy and should not expect problems in meeting its short term obligations.
  • With a decent Current ratio value of 1.84, BDSX is doing good in the industry, outperforming 75.25% of the companies in the same industry.
  • BDSX has a Quick Ratio of 1.84. This is a normal value and indicates that BDSX is financially healthy and should not expect problems in meeting its short term obligations.
  • BDSX has a better Quick ratio (1.84) than 78.22% of its industry peers.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.84
BDSX Yearly Current Assets VS Current LiabilitesBDSX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • BDSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.72%, which is quite impressive.
  • The Revenue has grown by 22.29% in the past year. This is a very strong growth!
  • The Revenue has been growing by 23.78% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)28.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.14%
Revenue 1Y (TTM)22.29%
Revenue growth 3Y9.37%
Revenue growth 5Y23.78%
Sales Q2Q%19.93%

3.2 Future

  • BDSX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.43% yearly.
  • BDSX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.14% yearly.
EPS Next Y17.09%
EPS Next 2Y23.9%
EPS Next 3Y20.43%
EPS Next 5YN/A
Revenue Next Year20.62%
Revenue Next 2Y23.68%
Revenue Next 3Y23.14%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BDSX Yearly Revenue VS EstimatesBDSX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
BDSX Yearly EPS VS EstimatesBDSX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BDSX. In the last year negative earnings were reported.
  • Also next year BDSX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDSX Price Earnings VS Forward Price EarningsBDSX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDSX Per share dataBDSX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • BDSX's earnings are expected to grow with 20.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.9%
EPS Next 3Y20.43%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BDSX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIODESIX INC

NASDAQ:BDSX (2/20/2026, 8:18:26 PM)

After market: 13.19 0 (0%)

13.19

+0.44 (+3.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-03
Earnings (Next)02-26
Inst Owners16.71%
Inst Owner Change13.46%
Ins Owners23.96%
Ins Owner Change0.44%
Market Cap104.99M
Revenue(TTM)80.17M
Net Income(TTM)-39.53M
Analysts80
Price Target33.15 (151.33%)
Short Float %7.15%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.12%
Min EPS beat(2)-14.78%
Max EPS beat(2)21.02%
EPS beat(4)2
Avg EPS beat(4)0.67%
Min EPS beat(4)-15.34%
Max EPS beat(4)21.02%
EPS beat(8)6
Avg EPS beat(8)4.87%
EPS beat(12)9
Avg EPS beat(12)3.64%
EPS beat(16)11
Avg EPS beat(16)2.38%
Revenue beat(2)2
Avg Revenue beat(2)4.02%
Min Revenue beat(2)1.75%
Max Revenue beat(2)6.29%
Revenue beat(4)3
Avg Revenue beat(4)-0.19%
Min Revenue beat(4)-9.55%
Max Revenue beat(4)6.29%
Revenue beat(8)5
Avg Revenue beat(8)-0.27%
Revenue beat(12)6
Avg Revenue beat(12)-1.75%
Revenue beat(16)8
Avg Revenue beat(16)0.07%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)22.27%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.31
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.56
EYN/A
EPS(NY)-3.25
Fwd EYN/A
FCF(TTM)-3.67
FCFYN/A
OCF(TTM)-3.52
OCFYN/A
SpS10.07
BVpS-0.22
TBVpS-2.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.56%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.82%
FCFM N/A
ROA(3y)-55.74%
ROA(5y)-49.96%
ROE(3y)-553.97%
ROE(5y)-391.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.1%
GM growth 5Y0.76%
F-Score3
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.57%
Cap/Sales 1.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.84
Altman-Z -7.19
F-Score3
WACC11.12%
ROIC/WACCN/A
Cap/Depr(3y)283.54%
Cap/Depr(5y)201.2%
Cap/Sales(3y)20.35%
Cap/Sales(5y)14.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.14%
EPS Next Y17.09%
EPS Next 2Y23.9%
EPS Next 3Y20.43%
EPS Next 5YN/A
Revenue 1Y (TTM)22.29%
Revenue growth 3Y9.37%
Revenue growth 5Y23.78%
Sales Q2Q%19.93%
Revenue Next Year20.62%
Revenue Next 2Y23.68%
Revenue Next 3Y23.14%
Revenue Next 5YN/A
EBIT growth 1Y6.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.4%
EBIT Next 3Y26.05%
EBIT Next 5YN/A
FCF growth 1Y34.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.44%
OCF growth 3YN/A
OCF growth 5YN/A

BIODESIX INC / BDSX FAQ

Can you provide the ChartMill fundamental rating for BIODESIX INC?

ChartMill assigns a fundamental rating of 3 / 10 to BDSX.


What is the valuation status of BIODESIX INC (BDSX) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIODESIX INC (BDSX). This can be considered as Overvalued.


Can you provide the profitability details for BIODESIX INC?

BIODESIX INC (BDSX) has a profitability rating of 1 / 10.


Can you provide the financial health for BDSX stock?

The financial health rating of BIODESIX INC (BDSX) is 2 / 10.